

Fig. 1.

| | | mortality | % | anaesth | technical |
|-----------------------------|---------|--------------|---------------|----------|-----------|
| Controls: | | 11/39 | (28,2) | 3 | 8 |
| IL-6: | | 10/80 | (12,5) | 5 | 5 |
| L.D. (Low Doses) | IL 0,1: | 0/12 | - | - | - |
| | IL 1: | 2/14 | (14,2) | 2 | - |
| | IL 10: | 2/20 | (10,0) | 2 | - |
| H.D. (High Doses) | IL 100: | 4/21 | (19,0) | 1 | 3 |
| | IL 500: | 2/13 | (15,4) | 0 | 2 |
| IL L.D.: | | 4/46 | (8,7) | | |
| IL H.D.: | | 6/34 | (17,6) | | |

Fig. 2




Fig. 3






Fig. 4

Hours after injection (100µg/Kg):

STAT-3



AP-1



NFkB




Fig. 5




Fig 6

IL-6 receptors in normal and cirrhotic rats: gp 130 and gp 80




Fig. 7




Fig. 8




Fig. 9

